Prolight Diagnostics CEO to BioStock: "We deliver on all goals”

Prolight Diagnostics' year-end report for 2023 shows that the company met all the goals for the year. The company's point-of-care analysis system has shown proof-of-performance for measurement of troponin in whole blood. In addition, the company has formed a Clinical Advisory Board and established an R&D manufacturing line for the upcoming pilot production. The goal for 2024 is to complete the development of the system for clinical validation.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/02/prolight-diagnostics-ceo-we-deliver-on-all-goals/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se